Guselkumab news

All news on Guselkumab (also known as TREMFYA): plants, production capacities, investments and involved companies.

22 December 2025

EC Approves Johnson & Johnson's TREMFYA® for Treating Plaque Psoriasis in Children

TREMFYA® gains EC approval for treating moderate to severe plaque psoriasis in children, marking the first IL-23 inhibitor for pediatric use.

Who will be producing Guselkumab in the future?

Find out with chemXplore Analytics